Alteplase for the Treatment of Catheter Occlusion in Pediatric Patients

Author:

Anderson Debra M1,Pesaturo Kimberly A2,Casavant Jonathan3,Ramsey E Zachary4

Affiliation:

1. Debra M Anderson PharmD, Clinical Pharmacist, Department of Pharmacy, Harrington Memorial Hospital, Southbridge, MA

2. Kimberly A Pesaturo PharmD BCPS, at time of writing, Assistant Professor, Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences

3. Jonathan Casavant PharmD, PGY-2 Pharmacy Administration Resident, Department of Pharmacy, VA Puget Sound Health Care System, Seattle, WA

4. E Zachary Ramsey PharmD, Clinical Specialist, Pediatric Cardiology, Department of Pharmacy, The Children's Hospital of Philadelphia, PA

Abstract

OBJECTIVE To review the literature pertaining to the efficacy of alteplase for restoration of patency of occluded venous and dialysis catheters in pediatric patients. DATA SOURCES A MEDLINE search was conducted and cross-referenced with an EMBASE search through November 2012. Search terms included alteplase, tissue plasminogen activator, and catheter. STUDY SELECTION AND DATA EXTRACTION Search results were limited to humans, English language, and ages from neonates to 18 years. Pertinent studies discussing efficacy of alteplase for restoration of occluded venous or dialysis catheter function were included. Case reports, review articles, and studies that specified inclusion of hemophilia patients or more than 75% of children with malignancy were excluded. DATA SYNTHESIS Fibrinolytics are the drug class of choice for restoration of patency (defined as the ability to withdraw a blood sample) of thrombus-occluded catheters. The trials used to support Food and Drug Administration approval of alteplase for central venous catheter (CVC) occlusions generally had low pediatric enrollment; however, additional small studies are available that support use of alteplase for this indication in children. Alteplase doses of 0.5–2 mg instilled into the lumen of a CVC with dwell times ranging from 30 to more than 240 minutes plus the potential for repeat dosing were reported. Overall efficacy ranged from approximately 50% to 90%, with greater efficacy generally reported with larger doses and longer dwell times. Alteplase doses of 2–2.5 mg with dwell times of 60–120 minutes were observed in 2 studies of occluded peritoneal or hemodialysis catheters, in which efficacy was reported in 57–100% of cases. Limitations of current studies of alteplase for catheter occlusion in children include small study populations and relative lack of pediatric-specific prospective trials. CONCLUSIONS Alteplase appears to show efficacy for treatment of thrombus-related venous catheter occlusion in pediatric patients; however, data regarding its use in occluded dialysis catheters are limited.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3